Farhad Zaker

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2871291/publications.pdf

Version: 2024-02-01

24	244	1163117	996975
papers	citations	8	15
		h-index	g-index

25	25	25	423
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A study on the antitumoral and differentiation effects of peganum harmala derivatives in combination with atra on leukaemic cells. Archives of Pharmacal Research, 2007, 30, 844-849.	6.3	57
2	Diagnosis of factor XIII deficiency. Hematology, 2016, 21, 430-439.	1.5	28
3	Congenital Factor V Deficiency: Comparison of the Severity of Clinical Presentations among Patients with Rare Bleeding Disorders. Acta Haematologica, 2015, 133, 148-154.	1.4	25
4	miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-Î¹B target genes. Tumor Biology, 2016, 37, 14117-14128.	1.8	20
5	Detection of KIT and FLT3 mutations in acute myeloid leukemia with different subtypes. Archives of Iranian Medicine, 2010, 13, 21-5.	0.6	17
6	Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia. Iranian Journal of Basic Medical Sciences, 2020, 23, 800-809.	1.0	13
7	Pathogenic and therapeutic roles of cytokines in acute myeloid leukemia. Cytokine, 2021, 142, 155508.	3.2	12
8	Inhibitor development in patients with congenital factor VII deficiency, a study on 50 Iranian patients. Blood Coagulation and Fibrinolysis, 2019, 30, 24-28.	1.0	9
9	Inhibitor in Congenital Factor VII Deficiency; a Rare but Serious Therapeutic Challengeâ€"A Systematic Literature Review. Journal of Clinical Medicine, 2021, 10, 211.	2.4	8
10	Detection of nucleophosmin and FMS-like tyrosine kinase-3 gene mutations in acute myeloid leukemia. Annals of Saudi Medicine, 2011, 31, 45-50.	1.1	7
11	Evaluation of umbilical cord blood CD34+ hematopoietic stem cells expansion with inhibition of TGF-Î² receptorII in co-culture with bone marrow mesenchymal stromal cells. Tissue and Cell, 2016, 48, 305-311.	2.2	7
12	A study of the oxidation-induced conformational and functional changes in neuroserpin. Iranian Biomedical Journal, 2007, 11, 41-46.	0.7	7
13	Molecular and clinical profile of congenital fibrinogen disorders in Iran, identification of two novel mutations. International Journal of Laboratory Hematology, 2020, 42, 619-627.	1.3	6
14	Epigenetic changes in FOXO3 and CHEK2 genes and their correlation with clinicopathological findings in myelodysplastic syndromes. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 214-219.	0.9	6
15	Gene Expression and Methylation Pattern in HRK Apoptotic Gene in Myelodysplastic Syndrome. International Journal of Molecular and Cellular Medicine, 2016, 5, 90-9.	1.1	5
16	Use of antioxidant nanoparticles to reduce oxidative stress in blood storage. Biotechnology and Applied Biochemistry, 2022, 69, 1712-1722.	3.1	4
17	Effects of Reduced Mir-24 Expression on Plasma Methotrexate Levels, Therapy-Related Toxicities, and Patient Outcomes in Pediatric Acute Lymphoblastic Leukemia. Reports of Biochemistry and Molecular Biology, 2020, 8, 358-365.	1.4	3
18	The effect of polymorphisms of gamma-glutamyl hydrolase (GGH) gene on methotrexate-induced toxicity in acute lymphoblastic leukemia. Toxin Reviews, 2015, 34, 136-141.	3.4	2

#	Article	IF	Citations
19	Aberrant Methylation of APAF-1 Gene in Acute Myeloid Leukemia Patients. International Journal of Hematology-Oncology and Stem Cell Research, 2017, 11, 225-230.	0.3	2
20	Dose-dependent efficacy of antioxidant nanoparticles on red blood cells storage. Journal of Education and Health Promotion, 2021, 10, 256.	0.6	2
21	Detection and biological characteristic of FLT3 gene mutations in children with acute leukemia. Archives of Iranian Medicine, 2014, 17, 258-61.	0.6	2
22	Relationship Between Single-Nucleotide Polymorphisms of Tumor Necrosis Factor Alpha, Interleukin-10, Factor II and Factor V with Risk of Inhibitor Development in Patients with Severe Hemophilia A. Cardiovascular & Hematological Disorders Drug Targets, 2019, 19, 228-232.	0.7	1
23	Aberrant Methylation-Mediated Suppression of APAF1 in Myelodysplastic Syndrome. International Journal of Hematology-Oncology and Stem Cell Research, 2017, 11, 114-120.	0.3	1
24	How to Assess Founder Effect in Patients with Congenital Factor XIII Deficiency. International Journal of Hematology-Oncology and Stem Cell Research, 2020, 14, 265-273.	0.3	0